Discontinued — last reported Q4 '25
Eli Lilly SG&A increased by 14.3% to $3.13B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 29.2%, from $2.42B to $3.13B. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 14.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ4 2014
Last reportedQ4 2025
How to read this metric
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
Detailed definition
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Peer comparison
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
Metric ID:
is_selling_general_and_administrativeHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.69B | $1.58B | $1.59B | $1.56B | $1.63B | $1.61B | $1.64B | $1.75B | $1.93B | $1.80B | $1.92B | $1.95B | $2.12B | $2.10B | $2.42B | $2.47B | $2.75B | $2.74B | $3.13B |
| QoQ Change | — | -6.4% | +0.9% | -2.1% | +4.3% | -0.7% | +1.8% | +6.5% | +10.1% | -6.3% | +6.7% | +1.4% | +8.5% | -0.8% | +15.5% | +1.8% | +11.5% | -0.4% | +14.3% |
| YoY Change | — | — | — | — | -3.6% | +2.3% | +3.2% | +12.3% | +18.5% | +11.8% | +17.1% | +11.6% | +10.0% | +16.4% | +26.0% | +26.5% | +30.0% | +30.5% | +29.2% |
Range$1.56B – $3.13B
CAGR+14.8%
Avg YoY Growth+16.1%
Median YoY Growth+16.4%
Business Segments
Loading segment data...
SG&A at Other Companies
Frequently Asked Questions
- What is Eli Lilly's sg&a?
- Eli Lilly (LLY) reported sg&a of $3.13B in Q4 2025.
- How has Eli Lilly's sg&a changed year-over-year?
- Eli Lilly's sg&a increased by 29.2% year-over-year, from $2.42B to $3.13B.
- What is the long-term trend for Eli Lilly's sg&a?
- Over 4 years (2021 to 2025), Eli Lilly's sg&a has grown at a 14.6% compound annual growth rate (CAGR), from $6.43B to $11.09B.
- What does sg&a mean?
- The day-to-day costs of running the business and marketing its products.